Significant progress made to supply chain to support cost improvements and scaling SAN FRANCISCO – December 1, 2022 – Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC),

65% growth in year-to-date revenue 146% increase in unit sales through direct-to-consumer channels for the same period Entered into definitive agreement to acquire Reliefband  

Agreement expected to reduce product manufacturing and shipping costs SAN FRANCISCO – November 10, 2022 – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a commercial-phase health technology

Will Demo FDA-Approved ClearUP that Treats Sinus Pain and Congestion from Colds, Flu, and Allergies   SAN FRANCISCO – November 7, 2022 – Tivic Health® Systems, Inc.

SAN FRANCISCO, CA – November 7, 2022 – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine,

Company Intends to Dramatically Expand Product Offerings into Bioelectronic Treatment of Nausea CEO to Host Investor Call/Webcast on Wednesday, October 19th at 1:30 PM PT